Knobias Clip Report (07-30-2008) LXRX
Submitted By Knobias ClipReport
LXRX: Positive Phase I Trial of LX1031 for Irritable Bowel Syndrome
By Fain Hughes, fhughes@knobias.com
Lexicon Pharmaceuticals, Inc. (LXRX) has successfully completed a Phase 1 multiple-dose escalation study in normal volunteers with LX1031, its oral drug candidate for irritable bowel syndrome (IBS). The company plans to progress the new drug candidate into Phase 2 studies in the fourth quarter. LX1031 is one of four programs in human clinical trials as part of Lexicon’s 10TO10 program.
LX1031 is designed to treat symptoms associated with IBS by decreasing the production of serotonin in the gastrointestinal tract. Serotonin is a key regulator of gastrointestinal sensation and motility. Importantly, the study showed that LX1031 decreased urinary 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin and biomarker for serotonin production, at all dose levels tested as compared to the placebo group. These results are consistent with a significant reduction in gastrointestinal serotonin synthesis.
Visit 1800blogger to see all of our industry leading blogs.
